|
First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors. |
|
|
Consulting or Advisory Role - Chugai Pharma; G1 Therapeutics; Vertex |
Research Funding - Pfizer (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma; Astex Pharmaceuticals; Genentech; Novartis |
Speakers' Bureau - Genentech |
Research Funding - Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst) |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer |
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer |
Research Funding - Astellas Pharma; Exelixis; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Pfizer; Pfizer (I) |
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Employment - Bristol-Myers Squibb; Pfizer |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Pfizer |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genentech; Lilly |
Research Funding - Millennium (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Genentech; Lilly |